0 Items
Toll Free (US) - +1-866-598-1553
sales@precisionbusinessinsights.com
Peptide Cancer Vaccine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

Peptide Cancer Vaccine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00 – $ 8,900.00

Peptide Cancer Vaccine Market: By Type (Multivalent Peptide Vaccine, Peptide Cocktail Type, Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Hybrid Peptide Vaccine, Others), By Application (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others), and Geography.

Request Sample Request Methodology
Request Sample Read More
$ PRICE - $ 3,000.00 – $ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00 – $ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:
Report

Description

Peptide Cancer Vaccine Market size was valued at USD 547.6 million in 2021. It is expected to reach a value of USD 1,501.5 million by 2028, growing at a CAGR of 15.5% during the forecast period from 2022 to 2028. The global market provides a detailed overview, which has been segmented by type, and application. The peptide cancer vaccine market has been segmented into Multivalent Peptide Vaccines, Peptide Cocktail Types, Personalized Peptide Vaccines, Peptide-Pulsed Dendritic Cancer Vaccines, Hybrid Peptide Vaccine, and Others. The peptide cocktail type segment is likely the most significant and fastest-growing in terms of type.  Based on the application, the peptide cancer vaccine is segmented into Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Others. According to precision business insights, the breast cancer segment is predicted to register the fastest growth rate during the forecast period.

Key Development:

In December 2021, ISA pharmaceuticals presented key learnings in cancer vaccine development in an educational session at the ESMO Immune-Oncology Congress 2021.

Peptide Cancer Vaccine Market

MARKET SUMMARY
-
15.5%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 15.5%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Peptide Cancer Vaccine Market

  • The peptide cancer vaccine market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The peptide cancer vaccine market report gives historical, current, and future market sizes (US$ Mn) based on by type, application and geography.
Key Players
  • Antigen Express
  • BioLife Science
  • Boston Biomedical
  • Enzo Life Science
  • Generex Biotechnology
Peptide Cancer Vaccine Market Dynamics

The ability to quickly synthesize, prepare and use peptide vaccines, their use in clinical settings, and adaptability to changing antigens. Reduced risk of anaphylaxis caused by antigens are benefits that are anticipated to drive market growth for peptide cancer vaccines shortly.

North-America Got Significant Share

Peptide Cancer Vaccine Market

The North American market is expected to witness the largest market share during the forecast period.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Peptide Cancer Vaccine Market Segmentation

segmentation-block-image

By Type

    • Multivalent Peptide Vaccine,
    • Peptide Cocktail Type,
    • Personalized Peptide Vaccine,
    • Peptide-Pulsed Dendritic Cancer Vaccine,
    • Hybrid Peptide Vaccine,
    • Others
segmentation-block-image

By Application

    • Breast Cancer,
    • Lung Cancer,
    • Melanoma,
    • Prostate Cancer and
    • Others
segmentation-block-image

By Geography

Location

GEOGRAPHY

Frequently Asked Questions

The global peptide cancer vaccine market growing at a CAGR of 15.5% during 2022-28

The major players in the global peptide cancer vaccine market are TapImmune, Merck, BrightPath Biotherapeutics, Sellas, BioLife Science, Boston Biomedical, VAXON Biotech, Lytix Biopharma, ISA Pharmaceuticals, Generex Biotechnology, and OncoTherapy Science.

North America is the fastest-growing region for the peptide cancer vaccine market

Report

Table Of Content

1. Executive Summary
2. Global Peptide Cancer Vaccine Market Introduction
2.1. Global Peptide Cancer Vaccine Market – Taxonomy
2.2. Global Peptide Cancer Vaccine Market –Definitions
2.2.1. By Type
2.2.2. By Application
2.2.3. By Region
3. Global Peptide Cancer Vaccine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Peptide Cancer Vaccine Market Dynamic Factors – Impact Analysis
3.6. Global Peptide Cancer Vaccine Market – Competition Landscape
4. Global Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Peptide Cancer Vaccine Market, By Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
5.1. Multivalent Peptide Vaccine
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Peptide Cocktail Types
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Personalized Peptide Vaccine
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Peptide-Pulsed Dendritic Cancer Vaccine
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Hybrid Peptide Vaccine
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Peptide Cancer Vaccine Market, By Application, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
6.1. Breast Cancer
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Lung Cancer
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Melanoma
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Prostate Cancer
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. Global Peptide Cancer Vaccine Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Region, 2022 – 2028
8. North America Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Multivalent Peptide Vaccine
8.1.2. Peptide Cocktail Type
8.1.3. Personalized Peptide Vaccine
8.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
8.1.5. Hybrid Peptide Vaccine
8.1.6. Others
8.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Breast Cancer
8.2.2. Lung Cancer
8.2.3. Melanoma
8.2.4. Prostate Cancer
8.2.5. Others
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
8.5. North America Peptide Cancer Vaccine Market Dynamics – Trends
9. Europe Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Multivalent Peptide Vaccine
9.1.2. Peptide Cocktail Type
9.1.3. Personalized Peptide Vaccine
9.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
9.1.5. Hybrid Peptide Vaccine
9.1.6. Others
9.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Breast Cancer
9.2.2. Lung Cancer
9.2.3. Melanoma
9.2.4. Prostate Cancer
9.2.5. Others
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Europe Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
9.5. Europe Peptide Cancer Vaccine Market Dynamics – Trends
10. Asia-Pacific Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Multivalent Peptide Vaccine
10.1.2. Peptide Cocktail Type
10.1.3. Personalized Peptide Vaccine
10.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
10.1.5. Hybrid Peptide Vaccine
10.1.6. Others
10.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Breast Cancer
10.2.2. Lung Cancer
10.2.3. Melanoma
10.2.4. Prostate Cancer
10.2.5. Others
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
10.5. Asia-Pacific Peptide Cancer Vaccine Market Dynamics – Trends
11. Latin America Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
11.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Multivalent Peptide Vaccine
11.1.2. Peptide Cocktail Type
11.1.3. Personalized Peptide Vaccine
11.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
11.1.5. Hybrid Peptide Vaccine
11.1.6. Others
11.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Breast Cancer
11.2.2. Lung Cancer
11.2.3. Melanoma
11.2.4. Prostate Cancer
11.2.5. Others
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
11.5. Latin America Peptide Cancer Vaccine Market Dynamics – Trends
12. Middle East and Africa Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
12.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Multivalent Peptide Vaccine
12.1.2. Peptide Cocktail Type
12.1.3. Personalized Peptide Vaccine
12.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
12.1.5. Hybrid Peptide Vaccine
12.1.6. Others
12.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Breast Cancer
12.2.2. Lung Cancer
12.2.3. Melanoma
12.2.4. Prostate Cancer
12.2.5. Others
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
12.5. MEA Peptide Cancer Vaccine Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Type Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Antigen Express
13.2.2. BioLife Science
13.2.3. Boston Biomedical
13.2.4. Enzo Life Science
13.2.5. Galena Biopharma
13.2.6. Generex Biotechnology
13.2.7. Generex Biotechnology Corporation
13.2.8. Immatics Biotechnologies
13.2.9. Immunomedics
13.2.10. ISA Pharmaceuticals
13.2.11. OncoTherapy Science
13.2.12. Sellas
13.2.13. TapImmune
13.2.14. VAXON Biotech
14. Research Methodology
15. Key Assumptions and Acronyms
Report

Company Profile

  • Antigen Express
  • BioLife Science
  • Boston Biomedical
  • Enzo Life Science
  • Galena Biopharma
  • Generex Biotechnology
  • Generex Biotechnology Corporation
  • Immatics Biotechnologies
  • Immunomedics
  • ISA Pharmaceuticals
  • OncoTherapy Science
  • Sellas
  • TapImmune

Description

Peptide Cancer Vaccine Market size was valued at USD 547.6 million in 2021. It is expected to reach a value of USD 1,501.5 million by 2028, growing at a CAGR of 15.5% during the forecast period from 2022 to 2028. The global market provides a detailed overview, which has been segmented by type, and application. The peptide cancer vaccine market has been segmented into Multivalent Peptide Vaccines, Peptide Cocktail Types, Personalized Peptide Vaccines, Peptide-Pulsed Dendritic Cancer Vaccines, Hybrid Peptide Vaccine, and Others. The peptide cocktail type segment is likely the most significant and fastest-growing in terms of type.  Based on the application, the peptide cancer vaccine is segmented into Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Others. According to precision business insights, the breast cancer segment is predicted to register the fastest growth rate during the forecast period.

Key Development:

In December 2021, ISA pharmaceuticals presented key learnings in cancer vaccine development in an educational session at the ESMO Immune-Oncology Congress 2021.

Reviews

There are no reviews yet.

Be the first to review “Peptide Cancer Vaccine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX

QUICKLINKS
RESEARCH AREAS
PRESS RELEASE
CONTACT US
+1-866-598-1553
EMAIL
sales@precisionbusinessinsights.com
FOLLOW US
QUICK LINKS+
RESEARCH AREAS+
PRESS RELEASE+
CONTACT US+
+1-866-598-1553
sales@precisionbusinessinsights.com
FOLLOW US AT+